3 331

Cited 0 times in

Folfox4 as a Rescue Chemotherapy for Gemcitabine-Refractory Pancreatic Cancer

Authors
 Chung JW  ;  Jang HW  ;  Chung MJ  ;  Park JY  ;  Park SW  ;  Chung JB  ;  Song SY  ;  Bang SM 
Citation
 HEPATO-GASTROENTEROLOGY, Vol.60(122) : 363-367, 2013 
Journal Title
 HEPATO-GASTROENTEROLOGY 
ISSN
 0172-6390 
Issue Date
2013
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/adverse effects ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/mortality ; Prognosis
Keywords
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives* ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/adverse effects ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use ; Pancreatic Neoplasms/drug therapy* ; Pancreatic Neoplasms/mortality ; Prognosis
Abstract
BACKGROUND/AIMS: This phase II study assessed the efficacy and safety of FOLFOX4 as a rescue therapy in patients with gemcitabine-refractory pancreatic cancer. METHODOLOGY: The study included patients with advanced pancreatic cancer who had failed gemcitabine-based chemotherapy. FOLFOX4 was administered biweekly as follows: oxaliplatin, 85 mg/m² as a 2-hour infusion (day 1); leucovorin, 200 mg/m²/day as a 2-hour infusion (days 1 and 2); 5-fluorouracil, bolus 400 mg/m²/day and 600 mg/m²/day as a 22-hour infusion (days 1 and 2). RESULTS: Forty-four patients received a total of 264 cycles of chemotherapy. There was 1 complete response (2.2%), 4 partial responses (9.1%), and 13 stable diseases (29.5%). The objective response rate was 11.4% and the tumor stabilization rate was 40.9%. The median time to progression was 9.9 weeks (95%CI: 8.2-11.5) and the median overall survival was 31.1 weeks (95%CI: 24.4-37.9). The common adverse events were hematologic toxicities: grade 3 or 4 neutropenia in 19 patients (43.2%), anemia in 9 patients (20.5%), and thrombocytopenia in 6 patients (13.5%). Grade 3 or 4 neuropathy occurred in 4 patients (9.1%). CONCLUSIONS: In gemcitabine-refractory pancreatic cancer, FOLFOX4 showed encouraging activity and was generally well-tolerated. However, careful attention needs to be paid to hematologic toxicities.
DOI
23858557
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
7. Others (기타) > Dept. of Health Promotion (건강의학과) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Jang, Hui Won(장희원)
Chung, Moon Jae(정문재) ORCID logo https://orcid.org/0000-0002-5920-8549
Chung, Jae Bock(정재복)
Chung, Joo Won(정주원)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/87977
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse